{"entity":{"id":"rp-3467","kind":"drug","name":"RP-3467","aka":[],"tldr":"RP-3467 is an experimental small molecule enzyme inhibitor from Repare Therapeutics, in phase 1 trials for epithelial ovarian cancer, metastatic breast cancer and metastatic castration-resistant prostate cancer and other cancers; its current status is not stated.","summary":"RP-3467 is a small molecule enzyme inhibitor from Repare Therapeutics. A small-molecule inhibitor of the ATPase of DNA polymerase theta (Polθ), a synthetic-lethal target linked to BRCA mutations and other genomic changes; tested alone and with olaparib. Its furthest stage is phase 1, for epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer and pancreatic adenocarcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1 POLAR NCT06560632 terminated ('Sponsor decided to terminate study early'); Repare said in November 2025 it would no longer report POLAR topline data and was seeking to license the programme. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Repare Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525159942/d944012dex991.htm"},{"label":"Repare Therapeutics: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1808158/000119312525283314/d39095dex991.htm"},{"label":"Repare Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06560632"},{"label":"ClinicalTrials.gov: trials of RP-3467","url":"https://clinicaltrials.gov/search?intr=RP-3467"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["polq"],"drugs":[],"companies":["repare-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06560632"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"RP-3467","modality":"Small molecule enzyme inhibitor","mechanism":"A small-molecule inhibitor of the ATPase of DNA polymerase theta (Polθ), a synthetic-lethal target linked to BRCA mutations and other genomic changes; tested alone and with olaparib.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rp-3467/","neighbours":{"target":[{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/"}],"company":[{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/"}],"trial":[{"id":"nct06560632","kind":"trial","name":"Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors","route":"/trials/nct06560632/"}]}}